Tamoxifen is the type of selective estrogen receptor modulator (SERM) suggested for treating women having high breast cancer risk. From its 1998 approval, tamoxifen is being used for the treatment of millions of people diagnosed with the early stage, hormone receptor positive breast cancer post-surgery for reducing the possibility of recurrence. It’s a first treatment choice for premenopausal women. Nolvadex’s generic name is Tamoxifen. Tamoxifen has usage off-label to treat infertility, gynecomastia, idiopathic sclerosing mesenteritis, and retroperitoneal fibrosis.
Request for Analysis of COVID-19 Impact on Tamoxifen Market –
Tamoxifen is the kind of receptor modulator for selective estrogen. The Tamoxifen’s key pharmacologic action is blocking the effects that promote estrogen’s growth effects on breast cancer. Within bone cells, selective modulators of estrogen interact with the receptors just as estrogen does along with strengthening bones. Tamoxifen is accessible in several forms including powder, oral solution, capsules, and tablets.
Global Tamoxifen Market Dynamics
Developments in therapeutic indications and combination therapies for tamoxifen is expected to drive growth of the global tamoxifen market over the forecast period. For instance, Novartis, in 2018, received the designation of breakthrough therapy by the U.S. Food and Drug Administration (FDA) for Kisqali within Phase 3. The designation was on the basis of successful MONALEESA-7 phase 3 trials that demonstrated notable prolonged-free survival (PFS) of Kisqali + tamoxifen (or an aromatase inhibitor). Furthermore, rising number of non-government and government organizations investing for discovering tamoxifen’s more therapeutic applications, is in turn, expected to drive growth of the global tamoxifen market over the forecast period. For instance, Duchenne UK, Duchenne Parent Project, Monaco Association, and E-Rare, in 2017, jointly donated US$ 766,338 for clinical trial that aims to evaluate tamoxifen’s effects for the duchenne muscular dystrophy treatment.
However, the European Cancer Congress 2017 survey, found that tamoxifen’s cost surged by 10x from 2011 to 2016, in spite of being generic. This study found that cost of this drug was 20x the price within India. Such prices disparity, with no appropriate reimbursement hampers the acceptance for this drug. Moreover, tamoxifen therapy’s adverse effects including anxiety, painful urination, and vaginal discharge is expected to restrain growth of the global tamoxifen market over the forecast period.
Furthermore, breast cancer being increasingly prevalent among women, in both emerging and developed economies is the key factor expected to drive the global tamoxifen market growth over the forecast period. As per 2012 report by, World Cancer Research Fund International, over 1.7 million latest cases of breast cancer were detected in 2012 that reflected a rise by around 20% since 2008.
Request PDF Brochure Report –
Global Tamoxifen Market – Regional Insights
Based on geography, the global tamoxifen market is segregated into North America, Latin America, Europe, Asia Pacific, Africa, and Middle East. North America accounts for the highest market share, due to high price and high acceptance of this drug to treat breast cancer. For instance, as per the 2018 pricing details by GoodRx Inc., 30 tamoxifen 20mg tablets costs averagely over US$ 65.71. Furthermore, rising incidence of breast cancer is expected to propel growth of the North America tamoxifen market growth over the forecast period. As per the 2018 statistics by U.S. Breast Cancer Organization, over 12.5% women in the U.S. are expected to develop an invasive breast cancer through their lifetime. Moreover, over 266,120 women are expected to be detected with an invasive breast cancer in 2018, in the U.S.
Asia Pacific is expected to register robust growth in the global tamoxifen market during the forecast period, due to rising number of individuals vulnerable to several chronic diseases along with increasing initiatives in healthcare. For instance, as per the Lancet Oncology 2014 published article, breast cancers are expected to increase from below 60 cases /100,000 women aged between 55 and 69 years to above 100 cases /100,000 women till 2021, touching 2.5 Mn overall cases by 2021.
Global Tamoxifen Market – Competitive Landscape
Major players functioning in the global tamoxifen market are Teva Pharmaceutical Industries Ltd, Aegis pharmaceuticals, AstraZeneca plc, Watson laboratories, Inc., Mylan N.V., Apotex Inc., and Allergan plc. Players in the market are engaged on adoption of strategies including mergers and acquisition for providing modified research products for sustaining their presence within the market. For instance, Dare Bioscience Inc., in 2018, announced a merger with the Pear Tree Pharmaceuticals for procuring rights for developing PT-101, as the potential treatment of vulvar and vaginal atrophy for people suffering with hormone-receptive positive breast cancer. The PT-101 is the proprietary vaginal formulation which Pear Tree Pharmaceuticals is developing.
Reasons to Purchase this Report
Current and future of global Tamoxifen market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Global Tamoxifen Market Taxonomy
Based on dosage form,
- Oral Solution
Based on indication,
- Breast Cancer
Based on region,
- North America
- Latin America
- Asia Pacific
- Middle East
Major Point Answered in Tamoxifen Market Research Study are:
What will be the progress rate of the Tamoxifen Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Tamoxifen Market across different regions?
Who are the major vendors dominating the Tamoxifen industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Tamoxifen Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027